转移性肾细胞癌免疫治疗反应评估：临床实践中的开放性挑战。
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
机构信息
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
出版信息
Int J Mol Sci. 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263.
Abstract
Immunotherapy has changed the therapeutic scenario of metastatic renal cell carcinoma (mRCC), however the evaluation of disease response to immune-checkpoint inhibitors is still an open challenge. Response evaluation criteria in solid tumors (RECIST) 1.1 criteria are the cornerstone of response assessment to anti-neoplastic treatments, but the use of anti-programmed death receptor 1 (PD1) and other immunotherapeutic agents has shown atypical patterns of response such as pseudoprogression. Therefore, immune-modified criteria have been developed in order to more accurately categorize the disease response, even though their use in the everyday clinical practice is still limited. In this review we summarize the available evidence on this topic, with particular focus on the application of immune-modified criteria in the setting of mRCC.
摘要
免疫疗法改变了转移性肾细胞癌（mRCC）的治疗格局，然而，免疫检查点抑制剂治疗效果的评估仍然是一个尚未解决的挑战。实体瘤反应评估标准（RECIST）1.1 标准是抗肿瘤治疗反应评估的基石，但抗程序性死亡受体 1（PD1）和其他免疫治疗药物的使用显示出非典型的反应模式，如假性进展。因此，已经开发了免疫修正标准，以便更准确地对疾病反应进行分类，尽管它们在日常临床实践中的应用仍然有限。在这篇综述中，我们总结了这一主题的现有证据，特别关注免疫修正标准在 mRCC 中的应用。
相似文献
1
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.转移性肾细胞癌免疫治疗反应评估：临床实践中的开放性挑战。
Int J Mol Sci. 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263.
2
Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.索拉非尼与细胞因子诱导的杀伤细胞联合治疗转移性肾细胞癌：一种潜在的治疗方案。
Immunotherapy. 2017 Jun;9(8):629-635. doi: 10.2217/imt-2016-0133.
3
[Radiological monitoring of immunotherapy in renal cell carcinoma].[肾细胞癌免疫治疗的放射学监测]
Aktuelle Urol. 2021 Sep;52(5):474-480. doi: 10.1055/a-1489-2163. Epub 2021 Aug 24.
4
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.免疫疗法正在改变转移性肾细胞癌的一线治疗方法。
Clin Genitourin Cancer. 2019 Jun;17(3):e513-e521. doi: 10.1016/j.clgc.2019.01.017. Epub 2019 Feb 5.
5
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.基于 iRECIST 和 RECIST 1.1 标准评估程序性细胞死亡蛋白-1 抑制剂治疗转移性透明细胞肾细胞癌患者的影像学肿瘤反应比较。
Korean J Radiol. 2021 Mar;22(3):366-375. doi: 10.3348/kjr.2020.0404. Epub 2020 Nov 26.
6
Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.晚期肾细胞癌进展后的免疫治疗：病例报告及文献复习。
Immunotherapy. 2018 Sep;10(13):1123-1132. doi: 10.2217/imt-2018-0042.
7
Overview of current and future systemic therapy for metastatic renal cell carcinoma.转移性肾细胞癌当前和未来的系统治疗概述。
Jpn J Clin Oncol. 2019 May 1;49(5):395-403. doi: 10.1093/jjco/hyz013.
8
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.新型免疫治疗药物在转移性肾细胞癌中的新作用：从实验室到临床
Am Soc Clin Oncol Educ Book. 2015:e291-7. doi: 10.14694/EdBook_AM.2015.35.e291.
9
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.转移性肾细胞癌的免疫治疗：综述
Biomed Res Int. 2015;2015:367354. doi: 10.1155/2015/367354. Epub 2015 Jun 16.
10
IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.在免疫疗法新方法背景下用于转移性肾细胞癌的IMA901
Future Oncol. 2014 May;10(6):937-48. doi: 10.2217/fon.14.61.
引用本文的文献
1
Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy.病例报告：肾细胞癌的局部侵袭性甲状腺转移：新辅助治疗后的手术
Front Oncol. 2025 May 28;15:1543060. doi: 10.3389/fonc.2025.1543060. eCollection 2025.
2
Spatially segregated APOE macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma.空间隔离的载脂蛋白E巨噬细胞限制了透明细胞肾细胞癌的免疫治疗效果。
Theranostics. 2025 Apr 13;15(11):5312-5336. doi: 10.7150/thno.109097. eCollection 2025.
3
F-box protein FBXO21 overexpression inhibits the proliferation and metastasis of clear cell renal cell carcinoma and is closely related to the CREB pathway and tumor immune cell infiltration.F-box蛋白FBXO21的过表达抑制透明细胞肾细胞癌的增殖和转移，并与CREB通路及肿瘤免疫细胞浸润密切相关。
J Transl Med. 2025 Mar 15;23(1):335. doi: 10.1186/s12967-025-06356-y.
4
Comprehensive investigation of malignant epithelial cell-related genes in clear cell renal cell carcinoma: development of a prognostic signature and exploration of tumor microenvironment interactions.全面研究透明细胞肾细胞癌中恶性上皮细胞相关基因：预后标志物的开发及肿瘤微环境相互作用的探索。
J Transl Med. 2024 Jul 1;22(1):607. doi: 10.1186/s12967-024-05426-x.
5
Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework.在3P医学背景下，基于101组合机器学习计算框架对透明细胞肾细胞癌免疫原性细胞死亡相关特征进行多组学鉴定。
EPMA J. 2023 May 31;14(2):275-305. doi: 10.1007/s13167-023-00327-3. eCollection 2023 Jun.
6
Tumor infiltrating lymphocytes and radiological picture of the tumor.肿瘤浸润淋巴细胞和肿瘤的影像学表现。
Med Oncol. 2023 May 13;40(6):176. doi: 10.1007/s12032-023-02036-3.
7
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.治疗前可溶性 PD-L1 作为免疫检查点抑制剂治疗总生存期的预测因子：系统评价和荟萃分析。
Cancer Immunol Immunother. 2023 May;72(5):1061-1073. doi: 10.1007/s00262-022-03328-9. Epub 2022 Nov 16.
8
Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.整合分析与透明细胞肾细胞癌进展相关的基因组和免疫微环境特征：对预后和免疫治疗的影响。
Front Immunol. 2022 May 23;13:830220. doi: 10.3389/fimmu.2022.830220. eCollection 2022.
9
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.一线肾细胞癌中贝姆培加德西ukin联合纳武单抗：PIVOT - 02研究结果
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004419.
10
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).纳武利尤单抗治疗既往治疗的晚期食管鳞癌患者的 3 年随访和应答生存关系（ATTRACTION-3）。
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
本文引用的文献
1
Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?生物标志物在转移性肾细胞癌对新型免疫治疗药物的反应中是否起预测作用？
Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6.
2
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
3
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.针对肾细胞癌的 PD-1/PD-L1 通路。
Int J Mol Sci. 2019 Apr 4;20(7):1692. doi: 10.3390/ijms20071692.
4
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
5
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
6
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.irRECIST 用于评估纳武利尤单抗治疗转移性透明细胞肾细胞癌候选生物标志物反应：一项 II 期前瞻性临床试验分析。
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.
7
Hyperprogressive disease: recognizing a novel pattern to improve patient management.Hyperprogressive disease：认识一种新的模式以改善患者管理。
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2.
8
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药对比伊匹单抗单药治疗晚期黑色素瘤（CheckMate 067）：一项多中心、随机、III 期临床试验的 4 年结果。
Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22.
9
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.可切除肺癌的新辅助PD-1阻断治疗
N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251.
10
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
Zotero 插件